CEA Rebound After Discontinuation of Pre-Hepatectomy Chemotherapy Predicts Worse Outcomes After Resection of Colorectal Cancer Liver Metastases

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2024 Nov 8

PMID 39516416

Authors

Antony Haddad

Mateo Lendoire

Abhineet Uppal

Harufumi Maki

Ian Folkert

Yifan Wang

Reed I Ayabe

Timothy E Newhook

Yun Shin Chun

Ching-Wei D Tzeng

Jean-Nicolas Vauthey

Hop S Tran Cao

Affiliations

Soon will be listed here.

Abstract

Background: Carcinoembryonic antigen (CEA) levels may vary with administration and discontinuation of pre-hepatectomy chemotherapy in patients undergoing resection of colorectal cancer liver metastases (CLM). The prognostic significance of these changes, termed CEA dynamics, is unclear.

Patients And Methods: Consecutive patients undergoing hepatectomy for CLM (2001-2021) at a comprehensive cancer center were included. CEA dynamics were classified as CEA normal (CEA < 5 ng/mL before, during, and after chemotherapy), CEA decrease (elevated CEA levels that drop during and after chemotherapy), and CEA rebound (elevated CEA levels that drop during chemotherapy but rebound upon discontinuation). Recurrence-free (RFS), hepatic-specific disease-free (hDFS), and overall survival (OS) were compared across CEA dynamics groups.

Results: Of 903 patients, 254 (28%) were CEA normal, 423 (47%) were CEA decrease, and 226 (25%) were CEA rebound. Median RFS was 15.9 months, median hDFS was not reached, and median OS was 11.9 years for CEA normal patients. By comparison, CEA decrease and CEA rebound patients had shorter median RFS (12.2 months, P = 0.002 and 7.4 months, P < 0.001, respectively), shorter median hDFS (29.1 months, P = 0.003 and 14.8 months, P < 0.001, respectively), and shorter median OS (7.1 years, P = 0.131, and 4.9 years, P < 0.001, respectively). On multivariable analysis, CEA rebound was an independent predictor of worse RFS [hazard ratio (HR) 1.50, 95% confidence interval (CI) 1.16-1.93], hDFS (HR 1.39, 95% CI 1.03-1.88), and OS (HR 1.79, 95% CI 1.18-2.73). Among patients with CEA rebound, RAS-BRAF/TP53 comutation and multiple tumors predicted worse OS while APC mutation predicted improved OS.

Conclusion: CEA rebound between pre-hepatectomy chemotherapy discontinuation and CLM resection is associated with worse oncologic outcomes, particularly in patients with aggressive tumor biology, and may help frame patient and surgeon expectations ahead of CLM resection.

References

Meyerhardt J, Mangu P, Flynn P, Korde L, Loprinzi C, Minsky B . Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013; 31(35):4465-70. DOI: 10.1200/JCO.2013.50.7442. View

Takamoto T, Sugawara Y, Hashimoto T, Shimada K, Inoue K, Maruyama Y . Dynamic assessment of carcinoembryonic antigen in the first month after liver resection for colorectal liver metastases as a rapid-recurrence predictor. J Surg Oncol. 2016; 113(4):463-8. DOI: 10.1002/jso.24152. View

Zeineddine F, Zeineddine M, Yousef A, Gu Y, Chowdhury S, Dasari A . Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol. 2023; 7(1):16. PMC: 9925745. DOI: 10.1038/s41698-023-00353-4. View

Kishi Y, Abdalla E, Chun Y, Zorzi D, Madoff D, Wallace M . Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg. 2009; 250(4):540-8. DOI: 10.1097/SLA.0b013e3181b674df. View

Simoneau E, Vauthey J . Progression of Colorectal Cancer Liver Metastasis After Chemotherapy: A New Test of Time?. Ann Surg Oncol. 2018; 25(6):1469-1470. PMC: 5930027. DOI: 10.1245/s10434-018-6439-0. View

Tang F, Huang C, Tang Z, Lu S, Bai T, Huang Q . Prognostic role of serum carcinoembryonic antigen in patients receiving liver resection for colorectal cancer liver metastasis: A meta-analysis. World J Gastrointest Surg. 2024; 15(12):2890-2906. PMC: 10784827. DOI: 10.4240/wjgs.v15.i12.2890. View

Boyev A, Tzeng C, Maki H, Arvide E, Mrema D, Jain A . Local Therapy Improves Survival for Early Recurrence After Resection of Colorectal Liver Metastases. Ann Surg Oncol. 2023; 31(4):2547-2556. DOI: 10.1245/s10434-023-14806-4. View

MOERTEL C, Fleming T, Macdonald J, Haller D, Laurie J, Tangen C . An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993; 270(8):943-7. View

Kawaguchi Y, Kopetz S, Panettieri E, Hwang H, Wang X, Tran Cao H . Improved Survival over Time After Resection of Colorectal Liver Metastases and Clinical Impact of Multigene Alteration Testing in Patients with Metastatic Colorectal Cancer. J Gastrointest Surg. 2021; 26(3):583-593. DOI: 10.1007/s11605-021-05110-1. View

10.

MOERTEL C, OFallon J, Go V, Oconnell M, Thynne G . The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer. 1986; 58(3):603-10. DOI: 10.1002/1097-0142(19860801)58:3<603::aid-cncr2820580302>3.0.co;2-k. View

11.

Lendoire M, Maki H, Haddad A, Newhook T, Tzeng C, Vauthey J . Exceptional pathologic response to preoperative therapy in the context of mutational profiling for colorectal liver metastases. J Gastrointest Surg. 2024; 28(7):1181-1184. DOI: 10.1016/j.gassur.2024.05.002. View

12.

Karapetis C, Khambata-Ford S, Jonker D, OCallaghan C, Tu D, Tebbutt N . K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359(17):1757-65. DOI: 10.1056/NEJMoa0804385. View

13.

Maki H, Jain A, Haddad A, Lendoire M, Chun Y, Vauthey J . Locoregional treatment for colorectal liver metastases aiming for precision medicine. Ann Gastroenterol Surg. 2023; 7(4):543-552. PMC: 10319606. DOI: 10.1002/ags3.12689. View

14.

Brouquet A, Abdalla E, Kopetz S, Garrett C, Overman M, Eng C . High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011; 29(8):1083-90. PMC: 3068054. DOI: 10.1200/JCO.2010.32.6132. View

15.

Kawaguchi Y, Kopetz S, Newhook T, De Bellis M, Chun Y, Tzeng C . Mutation Status of , and is Superior to Mutation Status of Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases. Clin Cancer Res. 2019; 25(19):5843-5851. PMC: 6774854. DOI: 10.1158/1078-0432.CCR-19-0863. View

16.

Thirunavukarasu P, Talati C, Munjal S, Attwood K, Edge S, Francescutti V . Effect of Incorporation of Pretreatment Serum Carcinoembryonic Antigen Levels Into AJCC Staging for Colon Cancer on 5-Year Survival. JAMA Surg. 2015; 150(8):747-755. DOI: 10.1001/jamasurg.2015.0871. View

17.

Primrose J, Perera R, Gray A, Rose P, Fuller A, Corkhill A . Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014; 311(3):263-70. DOI: 10.1001/jama.2013.285718. View

18.

Haddad A, Lendoire M, Maki H, Kang H, Habibollahi P, Odisio B . Liver volumetry and liver-regenerative interventions: history, rationale, and emerging tools. J Gastrointest Surg. 2024; 28(5):766-775. DOI: 10.1016/j.gassur.2024.02.020. View

19.

Yoshino K, Osumi H, Ito H, Kamiimabeppu D, Ooki A, Wakatsuki T . Clinical Usefulness of Postoperative Serum Carcinoembryonic Antigen in Patients with Colorectal Cancer with Liver Metastases. Ann Surg Oncol. 2022; 29(13):8385-8393. DOI: 10.1245/s10434-022-12301-w. View

20.

Gold P, Freedman S . DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES. J Exp Med. 1965; 121:439-62. PMC: 2137957. DOI: 10.1084/jem.121.3.439. View